Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population

Indian Journal of Ophthalmology

Volumn 58, Issue 2, 2010, Pages 125-130

  Taneja, Rashi ^a   Malik, Pankaj ^a   Sharma, Mamta ^a   Agarwal, Mahesh C ^a  

^a Deen Dayal Upadhyay Hospital   (India)

Author keywords

Deferriprone; Desferrioxamine; Iron overload; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CATARACT; CHILD; EYE DISEASE; FEMALE; HUMAN; INFANT; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRESCHOOL CHILD; VISUAL ACUITY;

ADOLESCENT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CATARACT; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; EYE DISEASES; FEMALE; HUMANS; INFANT; IRON CHELATING AGENTS; MALE; PYRIDONES; RETINAL PIGMENT EPITHELIUM; VISUAL ACUITY; YOUNG ADULT;

EID: 77949593178     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.60083     Document Type: Article

References (14)

1. Lokeshwar MR, Shah N, Kanika S, Manglani M. Thalassemia. In: IAP textbook of paediatrics. 3rd ed. New Delhi: Jaypee Publishers; 2006. p. 622-630
2. Bloomfield SE, Markenson AL, Miller DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978;15:154-156
3. Red cells and bleeding disorders. In: Cotran RS, Kumar V, Collins T, editors. Robbins Pathologic Basis of Disease. 6th ed. W.B. Saunders Company; p. 618.
4. Doncker RD, Casteels I, Leys A, Missott en L. Desferrioxamine and ocular toxicity, casual or concomitant relationship. Bull Soc Belge Ophthalmol 1986;220:61-67
5. Davies SC, Hungerford JL, Arden GE, Marcus RE, Miller MH, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2:181-184
6. Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long term high dose subcutaneous desferrioxanine therapy. Can J Ophthalmol 1985;20:153-156
7. Olivieri NF, Buncic JR, Chew E. Visual and auditory neurotoxicity in patients receiving subcutaneos desferrioxamine infusions. N Engl J Med 1986;314:869-873
8. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984;68:873-877
9. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease relationship between structure, redox activity and toxicity. Am J Hematol 2003;73:200-210
10. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984;91:443-451
11. Iron overload. In: Guidelines for the clinical management of Thalassemia. Thalassemia International Federation (TIF). 2000. p. 20-35.
12. Gartaganis S, Ismiridis K, Papageorgiou O. Ocular abnormalities in patients with beta thalassemia. Am J Ophthalmol 1989;108:699-703.
13. Gaba A, Souza PD, Chandra J, Narayan S, Sen S. Ocular changes in beta thalassemia. Ann Ophthalmol 1998;30:357-360
14. Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S, et al. Ocular findings among thalassemia patients. Am J Ophthalmol 2006;142:704-705